Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?
| Autoři | |
|---|---|
| Rok publikování | 2015 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Expert Review of Hematology |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | http://www.tandfonline.com/doi/abs/10.1586/17474086.2015.1079123?journalCode=ierr20 |
| Doi | http://dx.doi.org/10.1586/17474086.2015.1079123 |
| Obor | Onkologie a hematologie |
| Klíčová slova | CD20; CD52; chronic lymphocytic leukemia; monoclonal antibodies; resistance; therapy |
| Přiložené soubory | |
| Popis | Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and monoclonal antibodies (mAbs) are important part of CLL treatment. The goal of this article was to summarize current literature on the position of mAbs in CLL treatment and to mention factors influencing effectiveness of mAbs in CLL. Several new mAbs have been developed and investigated in CLL over the past few years. Mainly anti-CD20 monoclonal antibodies are still used routinely in CLL therapy. Unfortunately, the clinical application of mAbs needs to be further improved. Novel combinations and sequences of mAbs with other compounds need to be studied in clinical trials in order to increase overall response rate and prolong remission duration. Mechanisms of action of mAbs or mechanisms of resistance to mAbs have to be also investigated to predict effectiveness of mAb in particular patient. 2015 © Informa UK, Ltd. |
| Související projekty: |